| A mapping literature review of medical cannabis clinical outcomes and quality of evidence in approved conditions in the USA from 2016 to 2019 S Jugl, A Okpeku, B Costales, EJ Morris, G Alipour-Haris, ... Medical Cannabis and Cannabinoids 4 (1), 21-42, 2021 | 33 | 2021 |
| Association between a deficit accumulation frailty index and mobility outcomes in older adults: Secondary analysis of the lifestyle interventions and independence for elders … JD Brown, G Alipour-Haris, M Pahor, TM Manini Journal of clinical medicine 9 (11), 3757, 2020 | 17 | 2020 |
| Fabrication and in-vitro evaluation of buccal mucoadhesive tablet of meloxicam M Arabi, SA Mortazavi, Z Jafariazar, H Farhadnejad, GA Harisa, Y Fatahi Iranian Journal of Pharmaceutical Research: IJPR 19 (3), 63, 2020 | 9 | 2020 |
| A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. Medical cannabis and cannabinoids … S Jugl, A Okpeku, B Costales, EJ Morris, G Alipour-Haris, ... | 5 | 2021 |
| Comparison of Pimavanserin Versus Quetiapine for Hospitalization and Mortality Risk Among Medicare Beneficiaries with Parkinson's Disease Psychosis G Alipour‐Haris, MJ Armstrong, M Okun, JD Brown Movement Disorders Clinical Practice 10 (3), 406-414, 2023 | 4 | 2023 |
| Suicidal ideation and suicide-attempt-related hospitalizations among people with Alzheimer’s disease (AD) and AD-related dementias in the United States during 2016–2018 G Alipour-Haris, MJ Armstrong, JL Sullivan, U Suryadevara, ... Journal of Clinical Medicine 11 (4), 943, 2022 | 3 | 2022 |
| Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison FL da Silva Machado, M Cañás, SV Doubova, MA Urtasun, GH Marín, ... Regulatory Toxicology and Pharmacology 144, 105485, 2023 | | 2023 |
| HPR14 Real-World Evidence (RWE) to Support Regulatory Submissions: Landscape Assessment & Review G Haris, V Acha, S Liu, M Burcu Value in Health 26 (6), S213, 2023 | | 2023 |
| CO10 Association of Pimavanserin with Mortality Compared to Quetiapine for Parkinson's Disease Psychosis in Medicare Beneficiaries: 2016-2018 GA Haris, JD Brown, M Armstrong, MS Okun Value in Health 25 (7), S305, 2022 | | 2022 |
| FOCUSED REVIEW OF MEDICATION REGIMEN COMPLEXITY AND DEPRESCRIBING RECOMMENDATIONS IN SLEEP APNEA GUIDELINES FOR PATIENTS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS. L Galiano, CH Zengotita, G Alipour-Haris, J Brown CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S20-S21, 2022 | | 2022 |
| A regulatory overview of biosimilars across selected countries L Lopes, GM Santos, S Doubova, L Pont, E Eworuke, M Canas, M Tuccori, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31 (S2), 489-490, 2022 | | 2022 |
| A Systematic Review and Economic Evaluation of Sumatriptan Nasal Spray Versus its Oral Tablet GA Haris, N Ayati, A Mehramizi, P Ghasemzadeh, M Arabi, S Nikfar Journal of Pharmacoeconomics and Pharmaceutical Management 7 (3/4), 61-69, 2021 | | 2021 |
| PMU25 Computable Phenotypes (CPS) for Identifying Individuals with MULTI-Morbidity from Real-World DATA (RWD): A Systematic Literature Review HG Alipour, P Li, J Bian, Y Guo, H Shao Value in Health 24, S149, 2021 | | 2021 |
| A Systematic Review and Economic Evaluation of Sumatriptan Nasal Spray Versus its Oral Tablet R TitleEconomic, GA Haris, N Ayati, A Mehramizi, P Ghasemzadeh, ... | | 2021 |
| Letter by Alipour Haris et al Regarding Article,“Marijuana Use Among Young Adults (18–44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor Surveillance System Survey … G Alipour Haris, A Sarayani, AG Winterstein Stroke 51 (5), e91-e91, 2020 | | 2020 |
Joshua D. BrownAssociate Professor, Center for Drug Evaluation & Safety, Pharmaceutical Outcomes & PolicyVerified email at ufl.edu
